Condition: Complicated Staphylococcus Aureus (S. Aureus) Infections (CSAI) · Sponsor: University Hospital, Basel, Switzerland
This prospective randomized, controlled interventional pilot trial, aims to compare the achievement of the optimal target concentration with continuously administered flucloxacillin (FLU) or cefazolin (CZO) coupled with TDM and subsequent dose adjustment versus standard of care (intermittent bolus application without TDM-guidance) in patients with complicated Staphylococcus aureus (S. aureus) infections (CSAI). The overall goal is to individualize and optimize antibiotic treatment in a very vulnerable group of patients overcoming the standard strategy of "one-dose-fits-all".
This description comes directly from the study's public registry record.
Michael Osthoff, PD Dr. med. · +41 61 328 54 20 · michael.osthoff@usb.ch
Sarah Dräger, Dr. med. · +41 61 328 77 11 · sarah.draeger@usb.ch
Always discuss trial participation with your own doctor first.
| University Hospital Basel, Division of Internal Medicine | Basel, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05655091